Significant Wednesday Options Trading: SLNO, FWRD, CELH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2025
0mins
Should l Buy SLNO?
Source: NASDAQ.COM
Forward Air Corp Options Activity: Forward Air Corp (FWRD) has seen a trading volume of 3,114 options contracts today, equating to about 311,400 underlying shares, which is 42.1% of its average daily trading volume over the past month. Notably, the $30 strike call option expiring on December 19, 2025, has recorded 1,309 contracts traded.
Celsius Holdings Inc Options Activity: Celsius Holdings Inc (CELH) has reported a significantly higher options volume of 22,905 contracts today, representing approximately 2.3 million underlying shares, or 42% of its average daily trading volume. The $62 strike call option expiring on October 17, 2025, has seen 1,225 contracts traded.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.770
Low
75.00
Averages
110.50
High
125.00
Current: 39.770
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses, highlighting significant transparency issues within the company.
- Allegation Details: The complaint claims that Soleno and its executives systematically minimized and failed to disclose substantial safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, which raises serious doubts about the drug's commercial viability and could undermine investor confidence.
- Investor Impact: The undisclosed safety risks associated with DCCR may lead to higher patient discontinuation rates, prescriber reluctance, and potential legal and reputational fallout, negatively affecting the company's market performance and investor sentiment.
- Action Recommendation: Affected investors are advised to apply for lead plaintiff status by May 5, 2026, to seek recovery in the lawsuit, emphasizing the legal rights and protective measures available to investors facing corporate misconduct.
See More
Class Action Lawsuit Announced Against Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for common stock purchasers between March 26 and November 4, 2025, indicating potential investor losses due to undisclosed risks.
- Compensation Structure: Participants in the class action may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights in securities litigation.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety evidence related to its DCCR drug clinical trials, which could lead investors to misjudge the company's future commercial viability and associated risks.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Soleno Therapeutics Faces Class Action Lawsuit from Shareholders
- Lawsuit Background: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and August 4, 2025, alleging misrepresentations regarding the company's Phase 3 clinical trial program for DCCR, which may have led to investor losses.
- Lawsuit Details: Investors wishing to serve as lead plaintiff must file papers by May 5, 2026, with the lead plaintiff representing other class members in directing the litigation, although non-lead plaintiffs can still share in any recovery.
- Law Firm Background: Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for clients, representing not only individual investors but also some of the largest public and private pension funds, showcasing its extensive experience in class action litigation.
- Fee Structure: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Stock Price Plunge: Soleno Therapeutics experienced a sharp 27% drop in stock price on November 4, 2025, following the release of its third-quarter financial results, indicating significant investor harm due to major disruptions in the commercial launch of its lead drug, DCCR.
- Undisclosed Safety Risks: The class action lawsuit alleges that Soleno systematically concealed critical safety evidence related to “excess fluid retention” in its Phase 3 clinical trials, leading to a 12% decline in stock value in August 2025, which undermined market confidence in the drug's commercial viability.
- Decline in Patient Engagement: Management disclosed a decrease in patient start forms and an increase in discontinuations within the Prader-Willi syndrome community, correlating with a 19% drop in share value starting September 10, 2025, reflecting a significant loss of investor confidence in DCCR.
- Legal Consultation Opportunity: Investors are encouraged to file a lead plaintiff motion by May 5, 2026, with the Portnoy Law Firm offering complimentary case evaluations to assist investors in pursuing claims for losses incurred due to corporate misconduct, highlighting the importance of legal recourse for affected investors.
See More
Investigation Launched into Soleno Therapeutics' Securities Violations
- Investor Loss Investigation: The Law Offices of Howard G. Smith have announced an investigation into Soleno Therapeutics regarding potential violations of federal securities laws, aiming to assist investors in recovering their losses.
- Stock Price Plunge: Following the release of a 415-page report by activist investor Scorpion Capital, Soleno's stock price fell by $9.27, or 11.98%, over two trading days, closing at $68.09, significantly harming investors.
- Patient Safety Concerns: Soleno disclosed in a Form 8-K to the SEC that a patient died after taking DCCR, causing the stock price to drop by $13.49, or 19.21%, over two days, closing at $56.72, further injuring investors.
- Financial Impact: In its Q3 2025 financial results, Soleno reported that the Scorpion Capital report disrupted DCCR's launch trajectory, leading to fewer patient start forms and increased discontinuations, resulting in a stock price decline of $16.98, or 26.59%, to close at $46.87.
See More
Securities Class Action Filed Against Soleno Therapeutics
- Lawsuit Background: A securities class action has been filed against Soleno Therapeutics (NASDAQ: SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, highlighting significant investor concerns regarding the company's future prospects.
- Stock Price Plunge: Following Soleno's disappointing report on DCCR (trademarked as VYKAT™ XR) on November 5, 2025, the stock price plummeted by 26% that day, indicating strong market skepticism about the safety and efficacy of its products.
- Safety Concerns: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR, including issues of fluid retention in clinical trial participants, leading to a severe misjudgment of the drug's commercial viability by investors.
- Market Trust Crisis: The trust crisis triggered by short seller Scorpion Capital's report led Soleno to acknowledge during its November 4, 2025 earnings call that its launch trajectory had been disrupted, resulting in fewer start forms and increased discontinuations for non-serious adverse events, further exacerbating investor panic.
See More
Class Action Lawsuit Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses, highlighting significant transparency issues within the company.
- Allegation Details: The complaint claims that Soleno and its executives systematically minimized and failed to disclose substantial safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, which raises serious doubts about the drug's commercial viability and could undermine investor confidence.
- Investor Impact: The undisclosed safety risks associated with DCCR may lead to higher patient discontinuation rates, prescriber reluctance, and potential legal and reputational fallout, negatively affecting the company's market performance and investor sentiment.
- Action Recommendation: Affected investors are advised to apply for lead plaintiff status by May 5, 2026, to seek recovery in the lawsuit, emphasizing the legal rights and protective measures available to investors facing corporate misconduct.
See More
Class Action Lawsuit Announced Against Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for common stock purchasers between March 26 and November 4, 2025, indicating potential investor losses due to undisclosed risks.
- Compensation Structure: Participants in the class action may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights in securities litigation.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety evidence related to its DCCR drug clinical trials, which could lead investors to misjudge the company's future commercial viability and associated risks.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Soleno Therapeutics Faces Class Action Lawsuit from Shareholders
- Lawsuit Background: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and August 4, 2025, alleging misrepresentations regarding the company's Phase 3 clinical trial program for DCCR, which may have led to investor losses.
- Lawsuit Details: Investors wishing to serve as lead plaintiff must file papers by May 5, 2026, with the lead plaintiff representing other class members in directing the litigation, although non-lead plaintiffs can still share in any recovery.
- Law Firm Background: Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for clients, representing not only individual investors but also some of the largest public and private pension funds, showcasing its extensive experience in class action litigation.
- Fee Structure: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Stock Price Plunge: Soleno Therapeutics experienced a sharp 27% drop in stock price on November 4, 2025, following the release of its third-quarter financial results, indicating significant investor harm due to major disruptions in the commercial launch of its lead drug, DCCR.
- Undisclosed Safety Risks: The class action lawsuit alleges that Soleno systematically concealed critical safety evidence related to “excess fluid retention” in its Phase 3 clinical trials, leading to a 12% decline in stock value in August 2025, which undermined market confidence in the drug's commercial viability.
- Decline in Patient Engagement: Management disclosed a decrease in patient start forms and an increase in discontinuations within the Prader-Willi syndrome community, correlating with a 19% drop in share value starting September 10, 2025, reflecting a significant loss of investor confidence in DCCR.
- Legal Consultation Opportunity: Investors are encouraged to file a lead plaintiff motion by May 5, 2026, with the Portnoy Law Firm offering complimentary case evaluations to assist investors in pursuing claims for losses incurred due to corporate misconduct, highlighting the importance of legal recourse for affected investors.
See More
Investigation Launched into Soleno Therapeutics' Securities Violations
- Investor Loss Investigation: The Law Offices of Howard G. Smith have announced an investigation into Soleno Therapeutics regarding potential violations of federal securities laws, aiming to assist investors in recovering their losses.
- Stock Price Plunge: Following the release of a 415-page report by activist investor Scorpion Capital, Soleno's stock price fell by $9.27, or 11.98%, over two trading days, closing at $68.09, significantly harming investors.
- Patient Safety Concerns: Soleno disclosed in a Form 8-K to the SEC that a patient died after taking DCCR, causing the stock price to drop by $13.49, or 19.21%, over two days, closing at $56.72, further injuring investors.
- Financial Impact: In its Q3 2025 financial results, Soleno reported that the Scorpion Capital report disrupted DCCR's launch trajectory, leading to fewer patient start forms and increased discontinuations, resulting in a stock price decline of $16.98, or 26.59%, to close at $46.87.
See More
Securities Class Action Filed Against Soleno Therapeutics
- Lawsuit Background: A securities class action has been filed against Soleno Therapeutics (NASDAQ: SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, highlighting significant investor concerns regarding the company's future prospects.
- Stock Price Plunge: Following Soleno's disappointing report on DCCR (trademarked as VYKAT™ XR) on November 5, 2025, the stock price plummeted by 26% that day, indicating strong market skepticism about the safety and efficacy of its products.
- Safety Concerns: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR, including issues of fluid retention in clinical trial participants, leading to a severe misjudgment of the drug's commercial viability by investors.
- Market Trust Crisis: The trust crisis triggered by short seller Scorpion Capital's report led Soleno to acknowledge during its November 4, 2025 earnings call that its launch trajectory had been disrupted, resulting in fewer start forms and increased discontinuations for non-serious adverse events, further exacerbating investor panic.
See More
